Overview of DAPA ECHO Trial

Author(s):

Key Takeaways

The DAPA ECHO trial focused on dapagliflozin's effects on myocardial performance in nondiabetic heart failure patients.
A randomized, double-blind, placebo-controlled design was employed, using echocardiography to assess cardiac function.
Significant improvements in myocardial performance indices were observed, indicating dapagliflozin's benefits beyond glycemic control.
The study supports dapagliflozin's use in enhancing cardiac function in heart failure patients without diabetes, broadening its therapeutic scope.

Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.

EP: 1.Overview of FINEARTS-HF Trial

EP: 2.Role of MRAs in HFmrEF and HFpEF

EP: 3.Overview of BB Use and Outcomes in HFmrEF and HFpEF

EP: 4.Multi-Modal Treatment Strategy for HFmrEF and HFpEF

EP: 5.Unmet Needs in the HFmrEF and HFpEF Landscape

Now Viewing

EP: 6.Overview of DAPA ECHO Trial

Video content above is prompted by the following:

Discuss the data presented at European Society of Cardiology Congress 2024 for the DAPA ECHO trial in which the effects of dapagliflozin on myocardial performance were studied in patients with nondiabetic heart failure.
What was the objective of this analysis?
How was this study designed, and what methodology was used?
What results were presented?
Provide your key takeaways from this study. What are the key clinical implications in using dapagliflozin in patients with nondiabetic heart failure?